Updated on 4 June 2015
Eppendorf marked sales USD598 million in 2014
Singapore: Biotech supplier company, Eppendorf marked sales $598 million (€531.1 million) in 2014, registering increase of 5.7 percent from 2013.
Income from operations (EBIT) rose to $107.7 million (€95.7 million) as compared to $105.63 (€93.8 million) in the previous year and net income declined to $73.98 million (€65.7 million) from $76 million (€67.5 million).
In 2014, the company made capital investments to expand the sales structures and to set-up production facilities to intriduce new product lines. Eppendorf marginally increased its expense on research and development from $31.76 million (€28.2 million) in 2013 to $33.1 million (€29.4 million) in 2014. (prior year: €28.2 million).
Manpower strength went up from 2848 to 2,927 worldwide.
Mr Detmar Ammermann, spokesman, Management Board and chief financial officer, Eppendorf said, "The outstanding performance of our employees, our rigorous implementation of our strategies and the positive developments on the market all resulted in very positive sales growth of 5.7 percent. On the basis of this solid result, we will continue to pursue our strategic goals and increase customer benefit sustainably."